← Leaderboards
Diane E Goade
University Of New Mexico
$1,564,681
Attributed
$1,564,681
Total exposure
11
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $354K · FY2005–09$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
Funding mix
By agency
NIH$1,564,681 · 11
By mechanism
R01$1,492,500 · 1
M01$72,181 · 10
Top collaborators
No co-investigators on record.
Most similar at University Of New Mexico
Same institution · by research overlap
- Laurie G Hudson$12,915,106
- Pamela Ranel Hall$5,053,117
- Jac A Nickoloff$7,240,937
- James M Gale$1,041,013
- Ronald D Ley$160,912
Others in their field
Top investigators on “Research Personnel”
- David Heimbrook · Leidos Biomedical Research, Inc.$701,463,488
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Leonard Freedman · Leidos Biomedical Research, Inc.$557,978,666
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David R. Weir · University Of Michigan At Ann Arbor$364,053,504
- Judith S. Currier · University Of California Los Angeles$284,675,012
Research focus
Research PersonnelGrantComputer Retrieval Of Information On Scientific Projects DatabaseFundingInstitutionResourcesUnited States National Institutes Of HealthSourceDrug Screening /EvaluationLaboratory MouseRelapse /RecurrenceDisease /Disorder Prevention /ControlDisease /Disorder ModelHerpesviridae VaccineT LymphocyteNonhuman Therapy EvaluationRadiobiologyImmunomodulatorsLatent Virus InfectionGenetically Modified AnimalsGene ExpressionGene Environment InteractionHost Organism InteractionCytokine
Grant awards (15)
INVESTIGATION OF THE NATURAL HISTORY OF WEST NILE VIRUS INFECTION, OR AT RISK$4,129
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: A PHASE III DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL OF LONG TERM$687
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: A PHASE III DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL OF LONG TERM$4,845
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: INVESTIGATION OF THE NATURAL HISTORY OF WEST NILE VIRUS INFECTIO$2,907
M01 · FY2008 · RR · contact PI
A PHASE I/KK RANDOMIZED PLACEBO-CONTROLLED TRIAL TO ASSESS THE SAFETY AND EFFIC$1,869
M01 · FY2007 · RR · contact PI
A PHASE III DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL OF LONG TERM THERAPY OF$467
M01 · FY2007 · RR · contact PI
A PHASE I/KK RANDOMIZED PLACEBO-CONTROLLED TRIAL TO ASSESS THE SAFETY AND EFFIC$2,320
M01 · FY2006 · RR · contact PI
A PHASE III DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL OF LONG TERM THERAPY OF$928
M01 · FY2006 · RR · contact PI
Reactivated HSV-1 disease in immune compromised hosts$300,000
R01 · FY2005 · DE
A PHASE III DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL OF LONG TERM THERAPY OF$37,857
M01 · FY2005 · RR
A PHASE I/KK RANDOMIZED PLACEBO-CONTROLLED TRIAL TO ASSESS THE SAFETY AND EFFIC$16,172
M01 · FY2005 · RR
Reactivated HSV-1 disease in immune compromised hosts$300,000
R01 · FY2004 · DE
Reactivated HSV-1 disease in immune compromised hosts$300,000
R01 · FY2003 · DE
Reactivated HSV-1 disease in immune compromised hosts$300,000
R01 · FY2002 · DE
Reactivated HSV-1 disease in immune compromised hosts$292,500
R01 · FY2001 · DE